Balasa Dinverno & Foltz’s Vertex Pharmaceuticals VRTX Stock Holding History

Balasa Dinverno & Foltz’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.17M	Buy	4,029 +2,098	+109%	+$604K	0.07%	110
2022 Q2	$544K	Buy	+1,931	New	+$517K	0.03%	190
2021 Q1	–	Sell	-984	Closed	-$233K	–	314
2020 Q4	$233K	Sell	984 -1,519	-61%	-$349K	0.02%	260
2020 Q3	$681K	Sell	2,503 -762	-23%	-$210K	0.06%	126
2020 Q2	$948K	Buy	3,265 +1,643	+101%	+$445K	0.11%	79
2020 Q1	$386K	Buy	+1,622	New	+$372K	0.05%	158

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Balasa Dinverno & Foltz's VRTX Position: Q3 2022 in Review

Balasa Dinverno & Foltz increased its Vertex Pharmaceuticals (VRTX) stake by 109% in Q3 2022, buying an estimated $604K and bringing the position to 4,029 shares worth $1.17M. The position accounts for 0.07% of the portfolio, ranked #110.

Balasa Dinverno & Foltz first reported a position in VRTX in Q1 2020 and has held it in 6 quarters since. 1,125 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Balasa Dinverno & Foltz held 4,029 shares of Vertex Pharmaceuticals worth $1.17M as of Q3 2022.
Balasa Dinverno & Foltz bought 2,098 Vertex Pharmaceuticals shares in Q3 2022, an estimated $604K.
Vertex Pharmaceuticals made up 0.07% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #110 holding.
Balasa Dinverno & Foltz first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 6 quarters since.
1,125 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.